- Completing $340m strategic
acquisition of BioVision
- Expanding facilities in Eugene, further growing kits and assays
portfolio
- Supporting the growing demand of the sector and
accelerating execution of strategic plan
CAMBRIDGE, England,
Oct. 27, 2021 /CNW/ --
Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life
sciences reagents and tools, today announces the successful
completion of its acquisition of BioVision and the expansion
of its immunoassay capacity in Eugene,
OR.
Across the life sciences sector, the events of the last 18
months have amplified the need for efficient workflows and robust
data generation, to enable the faster delivery of positive outcomes
for science and health. Widespread access to high-performance,
reproducible, off-the-shelf assays and kits has become invaluable
to enable the biopharma industry and academia to achieve meaningful
advances at pace. To further support the growing demand of the
sector and to strengthen its position in the assay market, Abcam
today announces two significant developments, accelerating the
execution of its strategic growth plan.
The addition of BioVision enhances Abcam's in-house
innovation and adds scale to support the biochemical
assay and cellular assay markets. The successful
acquisition brings BioVision's product portfolio, capabilities, and
70-strong expert development and manufacturing teams into Abcam.
The global research community will gain ready access to this
portfolio of biochemical and cell-based assays via Abcam's global
commercialization network.
Supplementing the acquisition, Abcam has doubled the footprint
of its immunoassay kit R&D and manufacturing facility in
Eugene, OR. This enhanced capacity
is another component of Abcam's growth journey in the US and will
further enable its commitment to support the research and biopharma
sector globally.
Alan Hirzel, CEO at Abcam,
commented: "We are delighted to welcome our new
colleagues to Abcam. Providing a platform for future growth and
addition of new product lines, the acquisition of BioVision and
expansion of our Eugene facility
reinforce our commitment to the acceleration of scientific
breakthroughs. Enabling scientists to reproducibly generate the
robust results they need, faster, is essential for the
delivery of new innovations that can positively impact us
all."
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life sciences organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's +1,600-strong team are
located in the world's leading life sciences research hubs,
complementing a global network of services and support.
To find out more, please visit www.abcam.com and
www.abcamplc.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abcam-completes-340m-strategic-acquisition-and-expands-kit-capacity-and-capability-301409062.html
SOURCE Abcam